Skip to Content

Join the 'Reminyl' group to help and get support from people like you.

Reminyl News

Dementia Meds May Lead to Harmful Weight Loss: Study

Posted 3 Aug 2015 by Drugs.com

MONDAY, Aug. 3, 2015 – A class of drugs widely used to treat dementia – called cholinesterase inhibitors – could cause harmful weight loss in some patients, a new study suggests. These medications include Aricept (donepezil), Razadyne (galantamine) and Exelon (rivastigmine). "Our study provides evidence in a large, real-world population that cholinesterase inhibitors may contribute to clinically significant weight loss in a substantial proportion of older adults with dementia," study lead author Dr. Meera Sheffrin, a geriatrics fellow in the School of Medicine, at the University of California, San Francisco, said in a university news release. One expert said the findings point out a common problem for Alzheimer's patients. "Weight loss is a concern, not only for patients but also for their overwhelmed caregivers, who keep struggling with multiple challenges, including providing their ... Read more

Related support groups: Weight Loss, Dementia, Alzheimer's Disease, Aricept, Donepezil, Exelon, Mild Cognitive Impairment, Rivastigmine, Arteriosclerotic Dementia, Galantamine, Reminyl, Cachexia, Razadyne, Namzaric, Razadyne ER, Tacrine, Cognex, Aricept ODT, Lewy Body Dementia, Donepezil/memantine

Alzheimer's Drugs May Benefit Heart, Study Finds

Posted 5 Jun 2013 by Drugs.com

WEDNESDAY, June 5 – Drugs used to treat early-stage Alzheimer's disease may also reduce patients' risk of heart attack and death, according to a new study. Researchers followed more than 7,000 Alzheimer's disease patients in Sweden for more than three years. Those taking cholinesterase inhibitors had a 38 percent lower risk of heart attack, a 26 percent lower risk of death from cardiovascular causes such as stroke and a 36 percent lower risk of death from any cause, compared to those who did not take the drugs. Patients who took the highest recommended doses of cholinesterase inhibitors (ChEIs) had the lowest risk of heart attack or death – 65 percent and 46 percent lower, respectively, than those who never took the drugs, according to the study, which was published online June 5 in the European Heart Journal. "If you translate these reductions in risk into absolute figures, it means ... Read more

Related support groups: Heart Attack, Alzheimer's Disease, Aricept, Myocardial Infarction, Donepezil, Exelon, Cardiovascular Risk Reduction, Rivastigmine, Galantamine, Reminyl, Razadyne, Razadyne ER, Aricept ODT

Some People With Alzheimer's Take Conflicting Drugs

Posted 28 Oct 2011 by Drugs.com

FRIDAY, Oct. 28 – Many Alzheimer's patients who take cholinesterase inhibitors to slow their brain disease also take drugs that counter the effects of those Alzheimer's medications, a new study says. Clinical trials have shown that cholinesterase inhibitors such as Aricept (donepezil) have a modest impact on the functional and cognitive decline caused by Alzheimer's disease, noted the researchers at the Group Health Research Institute in Seattle. "Cholinesterase inhibitors are today's primary therapy for slowing Alzheimer's disease," study leader Denise Boudreau said in an institute news release. "Anticholinergic properties are often found in drugs commonly used to treat gastrointestinal disorders, allergies, urinary incontinence, depression and Parkinson's disease, and they can have negative effects on cognition and function in the elderly. There's concern that if someone is taking ... Read more

Related support groups: Benadryl, Diphenhydramine, Oxybutynin, Alzheimer's Disease, Meclizine, Aricept, Dramamine, Donepezil, Ditropan, Oxytrol, Cogentin, Exelon, Benztropine, Scopolamine, Benadryl Allergy, Antivert, Artane, Bonine, Transderm-Scop, Rivastigmine

FDA Medwatch Alert: Reminyl (galantamine hydrobromide)

Posted 1 Apr 2005 by Drugs.com

Ortho-McNeil Neurologics modified the PRECAUTIONS section of the Prescribing Information for Reminyl, approved only for the treatment of mild to moderate Alzheimer’s Disease. The changes provide new safety information regarding the results of two randomized, placebo-controlled trials of 2 years duration in subjects with mild cognitive impairment (MCI). A total of 13 subjects on REMINYL (n=1026) and 1 subject on placebo (n=1022) died. The deaths were due to various causes which could be expected in an elderly population. About half of the REMINYL deaths appeared to result from various vascular causes (myocardial infarction, stroke), and sudden death. [March 31, 2005 - Letter - Ortho-McNeil Neurologics] Read more

Related support groups: Reminyl

FDA Medwatch Alert: Reminyl (galantamine hydrobromide)

Posted 26 Oct 2004 by Drugs.com

[October 26, 2004] FDA, Janssen Pharmaceutica Products, and Johnson & Johnson Pharmaceutical Research & Development notified healthcare professionals of reports of medication errors involving confusion between Reminyl, a drug approved for the treatment of mild to moderate dementia of the Alzheimer's type, and Amaryl (glimepiride), a product of Aventis Pharmaceuticals, indicated for the treatment of non-insulin dependent (Type 2) diabetes mellitus. These reports include instances in which Reminyl was prescribed but Amaryl was incorrectly dispensed and administered instead, leading to various adverse events including severe hypoglycemia and one death.[UPDATE 12/23/2004] Letter to Pharmacists from Aventis Pharmaceuticals posted. [October 15, 2004 - Letter to Healthcare Professionals - Janssen][October 19, 2004 - Letter to Pharmacists - Janssen] PDF Format[November 5, 2004 - Letter to ... Read more

Related support groups: Reminyl

Ask a Question

Further Information

Related Condition Support Groups

Alzheimer's Disease

Reminyl Patient Information at Drugs.com